Press Release

MONTREAL, November 14th, 2023 – Replicor Inc. announced the disclosure of updated clinical data from the compassionate use of REP 2139-Mg and updated mechanistic data on the direct acting activity of REP 2139 in HDV infection at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) November 10-14, 2023 in Boston, USA (see here).

Key presentations covered the following:

  1. Updates on the compassionate use of REP 2139-Mg in French patients with decompensated cirrhosis (see here).
  2. Updates on the compassionate use of REP 2139-Mg in cirrhotic French patients who failed to respond to bulevirtide or experienced viral rebound during bulevirtide therapy (see here).
  3. The first data from compassionate use in new Austrian patients who failed to respond to bulevirtide (see here).
  4. Mechanistic data on the directing acting activity of REP 2139 against HDV replication (see here).
  5. Conserved antiviral activity of REP 2139 in all genotypes of HBV (see here and now published here).

Important highlights from these presentations included:

  1. Formal establishment of HDV cure and HBV functional cure in this difficult to treat patient population.
  2. Continued high rates of HDV clearance accompanied by HBsAg decline and loss.
  3. Elimination of HDV from the liver (in addition to clearance in the blood), with only trace HBV activity present, after only 10 weeks of therapy.
  4. Continued excellent safety profile.

Dr. Andrew Vaillant, CSO of Replicor commented, “REP 2139 is a unique bifunctional agent which directly targets HDV replication and subviral particle assembly.  These new data continue to reaffirm the potent and well tolerated antiviral activity of REP 2139-Mg, even in decompensated cirrhosis, and confirm for the first time in human patients the clearance of viremia from the liver.”

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV infection. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at